(NAUT) Nautilus Biotechnology, Inc. Business Model Canvas Research

Biopharma collaborators are a key source of insight for Nautilus Biotechnology, Inc., because drug discovery and biomarker teams help shape translational research and target-discovery use cases. In 2025, Nautilus was still pre-revenue, so these pilots matter both for product fit and for building future commercial customers.

• Use-case feedback from drug discovery teams
• Validates biomarker and translational workflows
• Creates pilots and future buyers

Nautilus Biotechnology, Inc. depends on cloud and software partners to handle high-volume proteomics data, so it can process, store, and share results without building every digital layer in-house. This fits a market where data creation hit about 149 zettabytes in 2024, making scalable compute and storage a core need.

• Scales compute on demand
• Stores large proteomics datasets
• Speeds data sharing and access
• Reduces internal build cost

Software and analytics development is core to Nautilus Biotechnology, Inc.’s proteomics model: it must turn massive raw instrument signals into clear protein IDs, quant signals, and workflow outputs. In FY2025, with the platform still pre-commercial, this code layer is what makes large-scale data usable for scientists.

• Interpret complex protein signals
• Automate workflow support
• Convert raw output into insight

That software moat matters because proteomics datasets are high-volume and noisy, so analysis speed and accuracy directly shape adoption and future revenue.

Customer validation and support are core to Nautilus Biotechnology, Inc. because early users need onboarding, training, and hands-on application help to run the platform well. In a capital-heavy life sciences tool business, this work also proves the system in real labs, improves retention, and feeds product iteration from each use case.

• Onboard early customers fast
• Train users for real workflows
• Use pilots to prove value
• Collect feedback to refine product
• Support drives retention and trust

Nautilus Biotechnology, Inc. needs lab space and instruments to run repeated prototyping, assay validation, and quality checks. In its latest 2025 filing, the Company was still pre-commercial, so lab infrastructure stays central to continuous testing and product refinement.

This asset base supports research speed and data quality, which matter more than scale at this stage.

• Supports nonstop experimentation
• Enables validation and QC

Nautilus Biotechnology, Inc. needs strong capital because platform development and commercialization are expensive, with funds going to R and D, hiring, manufacturing, and customer rollout. As a pre-scale life sciences company, liquidity is the key resource that keeps the platform moving before product sales can cover costs.

• Funds R and D and platform buildout.
• Pays for hiring and lab scale-up.
• Supports manufacturing and customer launch.
• Runway is critical before revenue scales.

Scalable data generation is central to Nautilus Biotechnology, Inc.’s value proposition because proteomics studies need large, high-quality datasets to find low-abundance signals and validate targets. The platform is built to support broader experimental coverage and bigger discovery and translational programs, which can make it more useful as study sizes rise.

• Higher volume supports larger cohorts
• Better coverage helps find rare proteins
• Fits discovery and translational work

Nautilus Biotechnology, Inc.’s recurring consumables model ties the platform to repeat-use reagents, so customers can keep workflows steady and reorder for ongoing experiments. In FY2025, the company still had no product revenue, so consumables remain a key future pull-through driver.

• Repeat purchases support workflow continuity.
• Replenishment fits ongoing assay use.
• Future revenue scales with installed base.

That model matters because it can turn one system placement into a steadier follow-on demand stream, which is more predictable than one-off instrument sales.

Nautilus Biotechnology, Inc. serves enterprise and research buyers that usually need close coordination, so dedicated account support is key for renewals, training, and expansion. In a still-developing, pre-scale model, this one-to-one service helps keep early users engaged and supports long-term retention.

• Supports renewals and training
• Helps manage expansions
• Builds retention through close follow-up

Nautilus Biotechnology, Inc. sells complex proteomics instruments, so structured onboarding is key to safe setup, correct workflows, and fewer user errors. Training helps labs move from first trial runs to routine use faster, which supports customer success and stickier adoption.

• Teach setup and QC steps
• Cut workflow mistakes
• Speed trial-to-routine use

Customer site demonstrations let potential buyers see Nautilus Biotechnology, Inc. in their own lab, so they can judge workflow fit, data output, and setup needs in real time. For a high-cost, technical platform, that lowers adoption risk because buyers do not have to rely only on brochures or remote calls.

• Shows the system in real use
• Reduces buying uncertainty fast
• Fits complex, high-ticket tools

Partner referrals matter for Nautilus Biotechnology, Inc. because collaborators, suppliers, and lab partners can introduce the Company to high-fit scientific buyers and build trust faster than cold outreach. In specialized proteomics markets, that can shorten sales cycles and lower customer acquisition cost, which is important for a pre-commercial Company with limited revenue.

• Trusted intros speed early pipeline growth.
• Scientific buyers value peer validation.
• Referrals cut sales friction and risk.

Contract research organizations serve many clients at once, so they need flexible proteomics tools that can switch fast between studies. Nautilus Biotechnology, Inc. was still pre-revenue in its latest 2025 filing, so CRO adoption matters as a path to repeat instrument pulls and consumable use, not just one-off sales.

• Multi-client workflows fit flexible analytics.
• Proteomics expands CRO service lines.
• Repeat use can lift recurring demand.

Core facilities are shared labs that buy advanced tools once and serve many users, so Nautilus Biotechnology, Inc. can reach dozens of researchers through one site. They need reliable uptime, support, and standard workflows, and that makes them a strong 2025-2026 channel for broad institutional exposure.

• One buyer, many users
• Need standard, repeatable workflows
• Drive multi-lab adoption

Nautilus Biotechnology, Inc. stays pre-revenue in FY2025, so laboratory and facilities costs sit at the center of its spend. These costs fund equipment, consumables, and overhead for prototyping, testing, and customer validation, which are needed to move its proteomics platform from development to operating readiness.

• Equipment and consumables drive lab spend.
• Facility overhead supports testing capacity.
• Builds prototyping and validation readiness.

Nautilus Biotechnology, Inc. is still pre-commercial, so sales, support, and G&A stay light today, but they will rise fast once commercialization starts. These costs cover sales and marketing, customer support, legal, finance, and public-company overhead, so they scale with headcount, channel build-out, and launch activity.

• Sales and support rise at launch.
• G&A includes legal and finance.
• Public-company costs expand with scale.

Nautilus Biotechnology, Inc. treats service and support contracts as a future recurring stream, covering maintenance, training, and technical help that can lift uptime and buyer trust. In its latest 2025 filings, Nautilus still reported $0 revenue, so this stream is not yet a cash driver but a key post-launch layer for retention.

• Maintenance and training can raise uptime.
• Support contracts add recurring revenue.
• Current 2025 revenue: $0.

For Nautilus Biotechnology, Inc., collaborative development fees can act as early, non-dilutive cash from pilot work and joint validation before scale sales start. In 2025, the Company remained pre-commercial, so these fees matter because they help fund assay expansion and can turn into future platform purchases once partners prove the tech.

• Paid pilot work funds validation
• Co-development lowers cash burn
• Joint tests can convert to sales